Repare Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Repare is committed to revolutionizing cancer treatments through its pioneering synthetic lethality approach. By harnessing the power of precision medicine, Repare aims to develop targeted therapies that address the underlying mechanisms of DNA damage repair in cancer cells. The company's corporate philosophy emphasizes scientific excellence, integrity, and a strong sense of responsibility towards advancing human health. Repare Therapeutics Inc prioritizes the needs of patients and strives to make a significant impact in the fight against cancer through cutting-edge research and development.

Repare Therapeutics Inc primarily operates in the United States and Canada.

Repare Therapeutics Inc, a leading biotechnology company, has accomplished several significant milestones. Firstly, it successfully completed its initial public offering (IPO) in June 2020, raising substantial capital to fuel its growth. Additionally, the company has made remarkable strides in advancing its innovative precision oncology platform, known as SNIPRx®, which utilizes synthetic lethality to target specific cancer vulnerabilities. Repare Therapeutics Inc has also forged strategic collaborations with renowned pharmaceutical companies, such as Bristol Myers Squibb, to further enhance its research and development efforts. These achievements demonstrate Repare Therapeutics Inc's commitment to revolutionizing cancer treatments through groundbreaking therapeutics and strategic partnerships.

Repare Therapeutics Inc is a pharmaceutical company specializing in precision oncology. Founded in 2016, the company is headquartered in Cambridge, Massachusetts, and has a research and development hub in Montreal, Canada. Repare Therapeutics aims to develop innovative drugs that target specific vulnerabilities in cancer cells through its proprietary synthetic lethality approach. With a focus on DNA repair pathways, the company harnesses the power of genomics, bioinformatics, and machine learning to identify potential drug targets. Repare Therapeutics has made significant advancements in novel therapeutics and is committed to revolutionizing cancer treatment through its cutting-edge research and development efforts.

The main competitors of Repare Therapeutics Inc in the market include leading biopharmaceutical companies like AstraZeneca, GlaxoSmithKline, Pfizer, and Novartis. These companies also focus on developing innovative and effective cancer treatments, similar to Repare Therapeutics Inc. As Repare Therapeutics Inc strives to advance its precision oncology pipeline and leverage its proprietary synthetic lethality approach, it faces competition from these established players in the industry.

Repare Therapeutics Inc is primarily active in the biotechnology industry.

Repare Therapeutics Inc. is a pharmaceutical company that focuses on developing precision oncology drugs. Their business model revolves around utilizing synthetic lethality, a cutting-edge approach to target specific genetic vulnerabilities in cancer cells. By exploiting the DNA repair pathways unique to cancer cells, Repare aims to develop novel therapies with enhanced efficacy and limited side effects. Their research and development efforts are driven by a robust pipeline of small molecule candidates, aiming to address the unmet medical needs of cancer patients. Repare Therapeutics Inc. is committed to revolutionizing cancer treatment through innovative precision medicine solutions.

P/E-talet för Repare Therapeutics är −1,48.

Det Repare Therapeutics KUV är 2,42.

AlleAktien Qualitätsscore för Repare Therapeutics är 4/10.

förväntade Repare Therapeutics omsättningen är 59,75 Mkr. USD.

förväntade Repare Therapeutics vinst är −97,72 Mkr. USD.

The company Repare Therapeutics Inc is a rising biotechnology company specializing in the discovery and development of new drugs for the treatment of cancer. The company was founded in 2016 and is headquartered in Montreal, Canada. Repare Therapeutics' business model is based on researching the fundamental mechanisms that lead to the development of cancer. The company uses an innovative approach called Synthetic Lethality to specifically identify weaknesses in cancer cells and then develop targeted drugs against these weaknesses. The company operates in two main areas, the discovery of new drugs and the clinical development of already identified candidates. Repare Therapeutics conducts intensive research and development to discover and develop new drug candidates. These drugs are then tested in clinical studies to evaluate their effectiveness and safety. Repare Therapeutics specializes in the development of drugs against cancer types that are traditionally difficult to treat. One such cancer is prostate cancer, which often exhibits high resistance to standard chemotherapy drugs. Repare Therapeutics focuses on innovative approaches, such as the development of drugs that target specific weaknesses in the DNA of cancer cells. In addition to drug development, Repare Therapeutics also collaborates with other biotechnology and pharmaceutical companies. The goal of these partnerships is to expand Repare Therapeutics' portfolio and further advance the research and development of new drugs. Repare Therapeutics' business model is focused on research and development, aiming to develop highly effective drugs against difficult-to-treat types of cancer. The company focuses on innovative approaches to specifically identify weaknesses in cancer cells. Through partnerships with other companies, the portfolio is expanded and research and development are advanced. Overall, Repare Therapeutics is a promising company that focuses on one of the biggest challenges in medicine: the development of effective and safe drugs for the treatment of cancer. With its innovative approaches and strong partnerships, the company has the potential to play a significant role in cancer research and contribute to better treating this disease in the future.

Repare Therapeutics delar ut en utdelning på 0 USD fördelad över utbetalningar per år.

Utbytet kan för närvarande inte beräknas för Repare Therapeutics eller så distribuerar bolaget inget utbyte.

ISIN för Repare Therapeutics är US7602731025.

WKN för Repare Therapeutics är A2P7AV.

Ticker-symbolen för Repare Therapeutics är RPTX.

Under de senaste 12 månaderna betalade Repare Therapeutics en utdelning på . Detta motsvarar en direktavkastning på ungefär . För de kommande 12 månaderna förväntas Repare Therapeutics betala en utdelning på 0 USD.

Aktiens direktavkastning för Repare Therapeutics är för närvarande .

Repare Therapeutics betalar ut dividenden kvartalsvis. Denna distribueras under månaderna .

Repare Therapeutics betalade utdelning varje år under de senaste 0 åren.

För de kommande 12 månaderna förväntas utdelningar uppgå till 0 USD. Detta motsvarar en utdelningsavkastning på 0 %.

Repare Therapeutics tilldelas sektorn 'Hälsa'.

För att få den senaste utdelningen från Repare Therapeutics den 2024-10-21 på 0 USD var du tvungen att ha aktien i ditt depå innan ex-dagen den 2024-10-21.

Utdelningen av den senaste dividenden skedde den 2024-10-21.

Under år 2023 delade Repare Therapeutics ut 0 USD i form av utdelningar.

Utdelningarna från Repare Therapeutics betalas ut i USD.